JP2007300862A - Collagen producing food - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide collagen producing food supplementing swallowing action with an elastase inhibitory agent and/or a collagen production-promoting agent having excellent elastase inhibitory activity and collagen production-promoting function, and preventing, protecting and improving aging. <P>SOLUTION: The collagen producing food enables supplement of swallowing action through the elastase inhibitory agent and/or the collagen production-promoting agent having extract of Cetraria islandica as active ingredients. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

The present invention is extracted from Iceland moss (Cetraria islandica), and blended with an excellent elastase inhibitory action and / or collagen production promoting action effective for preventing skin aging, or a swallowing action having a swallowing action Regarding food.

With aging, the activity of fibroblasts decreases, and qualitative and quantitative changes occur in collagen fibers, elastin, and acidic mucopolysaccharide, which are dermal matrix components. Collagen fibers become stiff due to the formation of abnormal aging bridges and lose their inherent elasticity. Elastin is denatured and disrupted, and elastin with a different amino acid composition is produced in a compensatory manner, resulting in functional impairment. As a result, the tissue loses flexibility and wrinkles, sagging, and joint pain occur. Collagen production promoters and elastase inhibitors have been developed for the purpose of preventing these physiological aging. (See Patent Document 1)

As for the lichen component, it has been clarified that the Sarcophagaceae has a skin-improving action, or the Musgogaceae lichen plant has a hyaluronidase inhibitory action, and therefore has a skin-improving action (see Patent Document 2). Lichens are symbiotic organisms of fungi and algae called certain lichens. Lichen has a metabolite peculiar to lichen called lichen component. Icelandic moss is used as an antitussive agent (see Patent Document 3) and a healthy stomach agent as Eilan Thai in Chinese medicine, and has been reported on antibacterial activity and antitumor activity against H. pylori (see Non-Patent Document 1). Red snow tea made of Lichenaceae lichens containing a hyaluronidase inhibitor has been developed as a dermatitis or antiallergic food (see Patent Document 4).

JP2005-220101A JP 2005-82531 A JP 2004-59463 A JP2003-212789 Antimicrob.AgentsChemother., Jan.1997,215-217

However, conventional elastase inhibitors or collagen production promoters themselves do not necessarily have sufficient anti-wrinkle effects, and when they are added to foods, an effective skin improvement effect is not sufficiently obtained. Furthermore, there is no proposal about the swallowing assistance effect of the lichen extract.

As a result of verifying the phenomenon accompanying photoaging and aging, which are major causes of wrinkle, from the viewpoint of elastase inhibitory action and collagen production promoting action, the present invention is particularly effective for the solvent extract of Iceland moss (Cetraria islandica). Found significant effectiveness.
ADVANTAGE OF THE INVENTION According to this invention, the foodstuff which is a solvent extract of Iceland moss and mix | blended the skin improvement agent which has a collagen production promotion effect and / or an elastase inhibitory effect is provided. Furthermore, according to this invention, the foodstuff which is a solvent extract of Iceland moss and mix | blended the swallowing agent which has a swallowing action is provided.

The Icelandic moss solvent extract of the present invention has an excellent elastase inhibitory effect, collagen production promoting effect, and swallowing assist effect, and foods formulated with this extract are early aging symptoms in the body It can improve joint pain, skin wrinkles, sagging, etc., and dysphagia associated with aging.

The Icelandic moss used in the present invention refers to the scientific name Cetraria islandica (L.) Ach. It is distributed over the northern hemisphere and the alpine ground. In the private sector, it has been used as a healthy stomach and antitussive (see World useful plant dictionary published by Heibonsha). In the present invention, not only a part of this Icelandic moss but also whole grass can be used as an extract. The Icelandic moss used in the present invention may be artificially produced by tissue culture.

The method of extracting Iceland moss in the present invention is not particularly limited, and examples thereof include a method of extracting from low temperature to warm using various solvents.

Specific extraction solvents include water, lower monohydric alcohols such as methanol and ethanol, liquid polyhydric alcohols such as glycerin, propylene glycol, dipropylene glycol and 1,3-butylene glycol, and lower alkyl esters such as ethyl acetate. It is illustrated, and these 1 type, or 2 or more types of mixed solvents can be used.

In the present invention, the Icelandic moss extract may be used as it is, but may be filtered and concentrated as necessary. In addition, the extract can be used after being fractionated and purified by a column chromatography method, a countercurrent distribution method or the like. Furthermore, after the above-mentioned product is dried under reduced pressure or freeze-dried, it can be prepared in the form of powder or paste, and can be appropriately formulated and used.

The method for preparing the extract used in the present invention is not particularly limited, and examples thereof include a method of extracting from low temperature to warm using various solvents.

Specific examples of the extraction solvent include lower monohydric alcohols such as water, methanol, and ethanol, liquid polyhydric alcohols such as glycerin, propylene glycol, dipropylene glycol, and 1,3-butylene glycol, and lower alkyl esters such as ethyl acetate. It is illustrated, and these 1 type, or 2 or more types of mixed solvents can be used.

The extract used in the present invention may be used as it is, but may be filtered and concentrated as necessary. The extract can also be used after being fractionated and purified by a column chromatography method, a countercurrent distribution method or the like. Furthermore, after the above-mentioned product is dried under reduced pressure or freeze-dried, it can be prepared in the form of powder or paste, and can be appropriately formulated and used.

Specific examples of foods to which the skin improving agent or swallowing agent of the present invention is blended include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, concentrated liquids and adjusting powders of these drinks; ice cream , Ice sherbet, shaved ice, etc .; noodles such as buckwheat, udon, harusame, gyoza peel, shumai peel, chinese noodles, instant noodles; candy, candy, gummi, gum, chocolate, snacks, biscuits, jelly, jam, Sweets such as cream and baked goods; processed fishery and livestock products such as kamaboko, ham, sausage; dairy products such as processed milk and fermented milk; fats and oils such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing And processed oils and fats; seasonings such as sauces and sauces; various forms of health and nutritional supplements such as tablets and granules Class; and other soups, stews, salads, prepared foods, pickles; and swallowing supplements and the like.

The blending amount of the skin improving agent or swallowing agent of the present invention is not particularly limited, and varies depending on the type, properties, quality, and expected effect of the product to be blended. In view of the above, it is preferable that the daily intake per adult is about 0.001 to 5000 mg per day.

If necessary, the food containing the skin improving agent or swallowing agent of the present invention may further contain components and additives used for pharmaceuticals, quasi-drugs, foods, etc., as long as the effects of the present invention are not impaired. Can be blended. The product of the present invention is preferably applied to humans, but is not particularly limited and can be applied to animals other than humans.

Next, although an example is given and explained, the present invention is not limited to these examples. Unless otherwise specified, “%” means “% by weight”.

An extract of Icelandic moss was prepared as follows.
Production Example 1
1000 g of 50 vol% ethanol solution was added to 100 g of Icelandic moss, extracted at 50 ° C. for 8 hours, cooled, and filtered to produce an Icelandic moss extract. The evaporation residue of the product was 0.73%.
Production Example 2
To 100 g of Icelandic moss, 2000 g of a 20 vol% ethanol solution was added and extracted at 50 ° C. for 8 hours. The extract was filtered, and the filtrate was concentrated to dryness under reduced pressure. The dried product was dissolved in 1000 g of 30% 1,3-butylene glycol and filtered to produce an Icelandic moss extract. The product evaporation residue was 0.98%.
Production Example 3
To 100 g of Icelandic moss, 2000 g of purified water was added and extracted at 50 ° C. for 8 hours. The extract was filtered, and the filtrate was concentrated to dryness under reduced pressure. The dried product was dissolved in 1000 g of 30% 1,3-butylene glycol and filtered to produce an Icelandic moss extract. The product evaporation residue was 1.02%.

Evaluation of Elastase Inhibitory Activity Elastase inhibitory activity was evaluated using pancreatic elastase (Type I manufactured by Sigma) and Succinyl-L-alanyl-L-alanyl-L-alanine-p-nitronide (manufactured by Sigma) as a synthetic substrate. Add 50 g of 50 vol% ethanol solution to 50 g of the dried product of the test sample other than Iceland Moss, extract at 50 ° C. for 8 hours, filter, concentrate under reduced pressure, dissolve the lyophilized powder in purified water, The solid concentration was 0.5 mg / mL. For Iceland moss, the evaporation residue of Production Example 1 was dissolved in purified water, and the extract solid content concentration was 0.5 mg / mL, which was used as a test sample.

Elastase activity inhibition test method A synthetic substrate is dissolved in dimethyl sulfoxide to a concentration of 15 mM, and 1 mL each is dispensed into a microtube and stored frozen. 0.1M before use
Dilute 20-fold with HEPES buffer (pH 7.5, 0.5 M NaCl) to 0.75 mM. Elastase is adjusted to 0.07 unit / mL with 50 mM Tris-HCl buffer (pH 8.5, 1 M NaCl). Synthetic substrate 100 μL, elastase 50 μL, and test sample 50 μL were added to 96-well plates, respectively, and incubated at 37 ° C. for 2 hours. Thereafter, the absorbance was measured at 405 nm with a plate reader.

The elastase inhibition rate was calculated from the measurement result by the following formula.
Elastase inhibition rate (%) = [1- (A−B) / (C−D)] × 100
A: Absorbance when sample solution is added and elastase is added B: Absorbance when sample solution is added and elastase is not added C: Absorbance when sample is not added and elastase is added D: Absorbance when sample is not added and elastase is not added At the time of addition, purified water and buffer were used instead.
Each inhibition rate is shown in Table 1.

As the evaluation test sample of the collagen production promoting action, the sample prepared in Production Example 3 was used. The concentration of human skin-derived fibroblasts is prepared in a MEM medium containing 10% fetal bovine serum (hereinafter abbreviated as FBS), seeded at 2 × 10 ⁴ cells / well in a 96-well plate, 37 ° C., 5% carbonic acid. The cells were cultured for 24 hours under gas. After culturing for 24 hours, after washing twice with PBS (−), a serum-free medium (5 g / L BSA, 0.01 mg / L EGF, 1 mg / L insulin, and 1 mg / L hydro hydrate added with the test sample) (MEM medium supplemented with cortisone) was cultured for 48 hours under the same conditions. After the culture, 100 μL of the culture supernatant was added to the ELISA plate and stored at room temperature for 18 hours. After washing with PBS containing 0.05% Tween-20 (PBS-T), PBS-T containing 1% skim milk was added and blocked at room temperature for 2 hours. The mixture was treated with an anti-human type I collagen antibody and a peroxidase standard anti-rat IgG antibody, and developed with a color kit for peroxidase. The amount of type I collagen contained in the culture supernatant was determined from the absorbance at 450 nm. The amount of control type I collagen was taken as 100% and calculated per unit protein. The Lowry method was used for protein quantification. The results are shown in Table 2.

Evaluation of the improvement effect on joint pain In order to examine the anti-aging effect, foods having the compositions shown in Examples 1 and 2 and Comparative Examples 1 and 2 below were used, and the improvement effect on joint pain and skin An evaluation test was conducted on the improvement effect on beam and sagging.

The subjects were 40 healthy women aged 50-65, who were painful on the knees and hips. The subjects were 10 people each and used the foods of Examples and Comparative Examples for 2 months. The improvement effect and the improvement effect on skin elasticity and sagging were investigated. The amount of intake was such that the amount of Icelandic moss extract was 1000 mg per day.

Example 1
Tablet-shaped dietary supplement The following mixture was tableted to produce a tablet-shaped dietary supplement.
Iceland moss extract (Production Example 1)
50 parts by mass Powdered sugar (sucrose) 188 parts by mass Glycerin fatty acid ester 12 parts by mass

Example 2
Granular dietary supplement The following mixture was formed into granules to produce a granular dietary supplement.
Iceland moss extract (Production Example 1)
50 parts by weight Beet oligosaccharide 1000 parts by weight Stevia extract 10 parts by weight

Comparative Example 1
Powdered sugar (sucrose) 250 parts by weight Glycerin fatty acid ester 15 parts by weight

Comparative Example 2
Beet oligosaccharide 1050 parts by mass Stevia extract 10 parts by mass

Evaluation of swallowing action Ten healthy women of 50 to 65 years of age extracted at random were used as subjects, and after eating and drinking Example 3 and Comparative Example 3, the improvement effect on ease of swallowing was examined.

Example 3
Dysphagia improving dietary supplement (gummy)
The granular nutritional supplement of Example 2 was arrange | positioned in the center, and 10 mass parts of Iceland moss extract (manufacture example 1) was mix | blended with the gelatin part of the gummy material.

Comparative Example 3
Gummy material Iceland moss extract of Example 3 (Production Example 1)
Ten parts by mass were changed to gelatin.

As is apparent from Table 3, when the dietary supplements of Examples 1 and 2 were used, the joint pain was reduced, the wrinkles of the corners of the eyes, and the skin tension, compared with the case of using the foods of Comparative Examples 1 and 2. It was observed that the improvement was in terms of sagging. As a result, it was confirmed that the food containing the Icelandic moss extract has an improving action such as reduction of joint pain, wrinkles and sagging of the skin.

As is apparent from Table 4, when the dietary supplement of Example 3 was used, the comparative example was much improved in terms of ease of swallowing related to swallowing action than when the food of Comparative Example 3 was used. It was confirmed that

Claims (2)

A food extract that is a solvent extract of Icelandic moss (Cetraria islandica) and that contains a skin improving agent having a collagen production promoting action and / or an elastase inhibiting action. A food extract that is a solvent extract of Icelandic moss and contains a swallowing agent having a swallowing action.